The AMA issued separate codes for subfascial and subcutaneous implantation of a tibial neuromodulation device.
Commentary|Articles|September 8, 2025
- Vol 53 No 09
- Volume 53
- Issue 09
Medicare proposed rule for 2026: CMS, what are you doing to us?
Author(s)Jonathan Rubenstein, MD, Mark Painter
Fact checked by: Benjamin P. Saylor, Strategic Content Lead
"Based on this proposal, some shifts may significantly impact the practice of urology," write Jonathan Rubenstein, MD, and Mark Painter.
Advertisement
Advertisement
On July 14, 2025, the Centers for Medicare & Medicaid Services (CMS) released the proposed rule for the Calendar Year 2026 Medicare Physician Fee Schedule (MPFS), which outlines proposed payment policies for the care of Medicare beneficiaries. Some significant changes are proposed, continuing the trend of shifting money away from surgical specialists and toward primary care providers.
Related to this article
Peter Clark, MD, discusses key updates to NMIBC guidelines, including revisions to risk stratification, the emerging role of biomarkers, and how to navigate treatment options for BCG-unresponsive disease.
Exploratory analyses suggest persistent immune remodeling after aglatimagene plus radiation in localized prostate cancer.
Heather Florio joins to discuss the potential role of supplements in pelvic and sexual health.
John P. Sfakianos, MD, discusses how ctDNA can be optimally integrated into bladder cancer clinical trials.
A recap of the FDA submissions and regulatory decisions in urology from September 2026.
Robert J. Motzer, MD, discusses the significance of the belzutifan plus lenvatinib approval, adverse event management with the combination, and the evolving role of HIF-2α inhibition in ccRCC.
Brian Mazzarella, MD, discusses the landscape for intermediate-risk prostate cancer and early VAPOR 2 findings on water vapor ablation.
Advertisement
Advertisement